Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure - 2Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 3Bomb blast in packed Nigerian mosque kills five
- 410 Delectable Specialty Mixed drinks
- 5Instructions to Warmly greet Certainty and Appeal
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- Palestinians tell BBC they were sexually abused in Israeli prisons
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Collierville residents with no power as temperatures plunge
- Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- Scientists find new clues to why female fertility declines with age
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
